As Eli Lil­ly's Moun­jaro pre­scrip­tions sky­rock­et, an­a­lyst pre­dicts $50B in year­ly tirzepatide sales

No mat­ter how you look at it, the obe­si­ty drug mar­ket is shap­ing up to be vast. And the spot­light right now is on Eli Lil­ly’s tirzepatide, which was ap­proved last year as Moun­jaro for type 2 di­a­betes and is al­ready un­der rolling sub­mis­sion as an obe­si­ty treat­ment.

The cur­rent flur­ry of in­ter­est comes in ad­vance of new da­ta ex­pect­ed this month from its sec­ond SUR­MOUNT study at the same time that Moun­jaro pre­scrip­tions are sky­rock­et­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER